Vitreous TIMP-1 levels associate with neovascularization and TGF-β2 levels but not with fibrosis in the clinical course of proliferative diabetic retinopathy

Journal of Cell Communication and Signaling

Volumn 7, Issue 1, 2013, Pages 1-9

  Van Geest, Rob J ^a   Klaassen, Ingeborg ^a   Lesnik Oberstein, Sarit Y ^a   Tan, H Stevie ^a   Mura, Marco ^a   Goldschmeding, Roel ^b   Van Noorden, Cornelis J F ^a   Schlingemann, Reinier O ^a,c,d  

^a UNIVERSITY OF AMSTERDAM   (Netherlands)

^b UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^c NETHERLANDS INSTITUTE FOR NEUROSCIENCE   (Netherlands)

^d ACADEMIC MEDICAL CENTER   (Netherlands)

Author keywords

CCN2; Diabetic retinopathy; Fibrosis; MMP 2; MMP 9; Neovascularization; TGF ; TIMP 1; VEGF

Indexed keywords

CONNECTIVE TISSUE GROWTH FACTOR; GELATINASE A; GELATINASE B; TISSUE INHIBITOR OF METALLOPROTEINASE 1; TRANSFORMING GROWTH FACTOR BETA2; VASCULOTROPIN;

ADULT; AGED; ARTICLE; CONTROLLED STUDY; DIABETIC RETINOPATHY; DISEASE COURSE; ENZYME LINKED IMMUNOSORBENT ASSAY; EPIRETINAL MEMBRANE; FEMALE; FIBROSIS; HUMAN; MAJOR CLINICAL STUDY; MALE; NEOVASCULARIZATION (PATHOLOGY); PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; RETINA MACULA HOLE; VITREOUS BODY; ZYMOGRAPHY;

EID: 84874929596     PISSN: 18739601     EISSN: 1873961X     Source Type: Journal    
DOI: 10.1007/s12079-012-0178-y     Document Type: Article

References (36)

1. Aiello LP, Wong JS (2000) Role of vascular endothelial growth factor in diabetic vascular complications. Kidney Int Suppl 77:S113-S119
2. Aiello LP, Avery RL, Arrigg PG, Keyt BA, Jampel HD, Shah ST, Pasquale LR, Thieme H, Iwamoto MA, Park JE, Nguyen HV, Aiello LM, Ferrara N, King GL (1994) Vascular endothelial growth factor in ocular fluid of patients with diabetic retinopathy and other retinal disorders. N Engl J Med 331:1480-1487
3. Babic AM, Chen CC, Lau LF (1999) Fisp12/mouse connective tissue growth factor mediates endothelial cell adhesion and migration through integrin alphavbeta3, promotes endothelial cell survival, and induces angiogenesis in vivo. Mol Cell Biol 19:2958-2966
4. Chapman HA (2004) Disorders of lung matrix remodeling. J Clin Invest 113:148-157
5. Connor TB Jr, Roberts AB, Sporn MB, Danielpour D, Dart LL, Michels RG, De Bustros S, Enger C, Kato H, Lansing M, Hayashi H, Glaser BM (1989) Correlation of fibrosis and transforming growth factor-beta type 2 levels in the eye. J Clin Invest 83:1661-1666
6. Descamps FJ, Martens E, Kangave D, Struyf S, Geboes K, Van Damme J, Opdenakker G, Abu El-Asrar AM (2006) The activated form of gelatinase B/matrix metalloproteinase-9 is associated with diabetic vitreous hemorrhage. Exp Eye Res 83:401-407
7. Fan WH, Pech M, Karnovsky MJ (2000) Connective tissue growth factor (CTGF) stimulates vascular smooth muscle cell growth and migration in vitro. Eur J Cell Biol 79:915-923
8. Frank RN (2004) Diabetic retinopathy. N Engl J Med 350:48-58
9. Frederiks WM, Mook OR (2004) Metabolic mapping of proteinase activity with emphasis on in situ zymography of gelatinases: review and protocols. J Histchem Cytochem 52:711-722
10. Guerin CJ, Hu L, Scicli G, Scicli AG (2001) Transforming growth factor beta in experimentally detached retina and periretinal membranes. Exp Eye Res 73:753-764
11. Hinton DR, He S, Jin ML, Barron E, Ryan SJ (2002) Novel growth factors involved in the pathogenesis of proliferative vitreoretinopathy. Eye (Lond) 16:422-428
12. Hinton DR, Spee C, He S, Weitz S, Usinger W, LaBree L, Oliver N, Lim JI (2004) Accumulation of NH2-terminal fragment of connective tissue growth factor in the vitreous of patients with proliferative diabetic retinopathy. Diabetes Care 27:758-764
13. Inoki I, Shiomi T, Hashimoto G, Enomoto H, Nakamura H, Makino K, Ikeda E, Takata S, Kobayashi K, Okada Y (2002) Connective tissue growth factor binds vascular endothelial growth factor (VEGF) and inhibits VEGF-induced angiogenesis. FASEB J 16:219-221
14. Jacqueminet S, Ben AO, Chapman MJ, Nicolay N, Foglietti MJ, Grimaldi BJL (2006) Elevated circulating levels of matrix metalloproteinase-9 in type 1 diabetic patients with and without retinopathy. Clin Chim Acta 367:103-107
15. Jang HS, Kim HJ, Kim JM, Lee YS, Kim KL, Kim JA, Lee JY, Suh W, Choi JH, Jeon ES, Byun J, Kim DK (2004) A novel ex vivo angiogenesis assay based on electroporation-mediated delivery of naked plasmid DNA to skeletal muscle. Mol Ther 9:464-474
16. Kita T, Hata Y, Arita R, Kawahara S, Miura M, Nakao S, Mochizuki Y, Enaida H, Goto Y, Shimokawa H, Hafezi-Moghadam A, Ishibashi T (2008) Role of TGF-beta in proliferative vitreoretinal diseases and ROCK as a therapeutic target. Proc Natl Acad Sci U S A 105:17504-17509
17. Kuiper EJ, de Smet MD, van Meurs JC, Tan HS, Tanck MW, Oliver N, Van Nieuwenhoven FA, Goldschmeding R, Schlingemann RO (2006) Association of connective tissue growth factor with fibrosis in vitreoretinal disorders in the human eye. Arch Ophthalmol 124:1457-1462
18. Kuiper EJ, Hughes JM, Van Geest RJ, Vogels IMC, Goldschmeding R, Van Noorden CJF, Schlingemann RO, Klaassen I (2007) Effect of VEGF-A on expression of profibrotic growth factor and extracellular matrix genes in the retina. Invest Ophthalmol Vis Sci 48:4267-4276
19. Kuiper EJ, Van Nieuwenhoven FA, de Smet MD, van Meurs JC, Tanck MW, Oliver N, Klaassen I, Van Noorden CJF, Goldschmeding R, Schlingemann RO (2008) The angio-fibrotic switch of VEGF and CTGF in proliferative diabetic retinopathy. PLoS One 3:e2675
20. Leask A, Parapuram SK, Shi-Wen X, Abraham DJ (2009) Connective tissue growth factor (CTGF, CCN2) gene regulation: a potent clinical bio-marker of fibroproliferative disease? J Cell Commun Signal 3:89-94
21. Matsuo T, Okada Y, Shiraga F, Yanagawa T (1998) TIMP-1 and TIMP-2 levels in vitreous and subretinal fluid. Jpn J Ophthalmol 42:377-380
22. Mayrand D, Laforce-Lavoie A, Larochelle S, Langlois A, Genest H, Roy M, Moulin VJ (2012) Angiogenic properties of myofibroblasts isolated from normal human skin wounds. Angiogenesis 15:199-212
23. McLennan SV, Wang XY, Moreno V, Yue DK, Twigg SM (2004) Connective tissue growth factor mediates high glucose effects on matrix degradation through tissue inhibitor of matrix metalloproteinase type 1: implications for diabetic nephropathy. Endocrinology 145:5646-5655
24. Mook OR, Van Overbeek C, Ackema EG, Van Maldegem F, Frederiks WM (2003) In situ localization of gelatinolytic activity in the extracellular matrix of metastases of colon cancer in rat liver using quenched fluorogenic DQ-gelatin. J Histochem Cytochem 38:295-304
25. Mook OR, Frederiks WM, Van Noorden CJF (2004) The role of gelatinases in colorectal cancer progression and metastasis. Biochim Biophys Acta 1705:69-89
26. Moussad EE, Brigstock DR (2000) Connective tissue growth factor: what's in a name? Mol Genet Metab 71:276-292
27. Salzmann J, Limb GA, Khaw PT, Gregor ZJ, Webster L, Chignell AH, Charteris DG (2000) Matrix metalloproteinases and their natural inhibitors in fibrovascular membranes of proliferative diabetic retinopathy. Br J Ophthalmol 84:1091-1096
28. Schlingemann RO, van Hinsbergh VW (1997) Role of vascular permeability factor/vascular endothelial growth factor in eye disease. Br J Ophthalmol 81:501-512
29. Sethi CS, Bailey TA, Luthert PJ, Chong NH (2000) Matrix metalloproteinase biology applied to vitreoretinal disorders. Br J Ophthalmol 84:654-666
30. Shimo T, Nakanishi T, Nishida T, Asano M, Kanyama M, Kuboki T, Tamatani T, Tezuka K, Takemura M, Matsumura T, Takigawa M (1999) Connective tissue growth factor induces the proliferation, migration, and tube formation of vascular endothelial cells in vitro, and angiogenesis in vivo. J Biochem 126:137-145
31. Suzuma K, Naruse K, Suzuma I, Takahara N, Ueki K, Aiello LP, King GL (2000) Vascular endothelial growth factor induces expression of connective tissue growth factor via KDR, Flt1, and phosphatidylinositol 3-kinase-Akt-dependent pathways in retinal vascular cells. J Biol Chem 275:40725-40731
32. Van Geest RJ, Klaassen I, Vogels IM, Van Noorden CJ, Schlingemann RO (2010) Differential TGF-β signaling in retinal vascular cells: a role in diabetic retinopathy? Invest Ophthalmol Vis Sci 51:1857-1865
33. Van Geest RJ, Lesnik-Oberstein SY, Tan HS, Mura M, Goldschmeding R, Van Noorden CJF, Klaassen I, Schlingemann RO (2012) A shift in the balance of vascular endothelial growth factor and connective tissue growth factor by bevacizumab causes the angiofibrotic switch in proliferative diabetic retinopathy. Br J Ophthalmol 96:587-590
34. Witmer AN, Vrensen GFJM, Van Noorden CJF, Schlingemann RO (2003) Vascular endothelial growth factors and angiogenesis in eye disease. Progr Retin Eye Res 22:1-29
35. Yoshida S, Ishikawa K, Matsumoto T, Yoshida A, Ishibashi T, Kono T (2010) Reduced concentrations of angiogenesis-related factors in vitreous after vitrectomy in patients with proliferative diabetic retinopathy. Graefes Arch Clin Exp Ophthalmol 248:799-804
36. Zhou X, Hu H, Huynh ML, Kotaru C, Balzar S, Trudeau JB, Wenzel SE (2007) Mechanisms of tissue inhibitor of metalloproteinase 1 augmentation by IL-13 on TGF-beta 1-stimulated primary human fibroblasts. J Allergy Clin Immunol 119:1388-1397